All articles tagged with #long acting injection
A new long-acting HIV prevention injection, cabotegravir, is set to be approved in England and Wales, offering an alternative to daily pills for those at risk who cannot take oral Prep, with rollout expected soon to help reach the goal of ending HIV transmissions by 2030.
The World Health Organization now recommends the use of lenacapavir, a long-acting injectable drug administered twice a year, as part of HIV prevention strategies, especially for high-risk groups, marking a significant shift from daily pills to less frequent, more convenient options amid funding challenges for HIV programs.
Researchers from the University of South Australia have developed a biodegradable, weekly injectable formulation of levodopa and carbidopa that could significantly improve Parkinson's disease treatment by maintaining steady drug levels, reducing pill burden, and enhancing patient adherence, with potential applications for other chronic diseases.
ViiV Healthcare has developed a new, stronger form of the HIV prevention drug cabotegravir, which could be administered as an injection every four months. The new formulation, called "cabotegravir ultra long-acting" (CAB-ULA), showed promising results in a trial, with fewer side effects and longer-lasting effects compared to the current form of the drug. If further trials are successful, this new long-acting injection could revolutionize HIV prevention and treatment.